Mizuho Securities USA’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Mizuho Securities USA’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-250,638	Closed	-$2.47M	–	240
2022 Q4	$2.47M	Sell	250,638 -194,319	-44%	-$1.95M	0.23%	79
2022 Q3	$4.38M	Buy	+444,957	New	+$4.4M	0.6%	59
2021 Q3	–	Sell	-57,650	Closed	-$559K	–	320
2021 Q2	$559K	Buy	+57,650	New	+$560K	0.05%	179

Mizuho Securities USA's BIOT Position: Q1 2023 in Review

Mizuho Securities USA sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 250,638 shares — an estimated $2.47M sold.

Mizuho Securities USA first reported a position in BIOT in Q2 2021 and held it in 3 quarters. The position peaked at $4.38M in Q3 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Mizuho Securities USA reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Mizuho Securities USA sold 250,638 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $2.47M.
Mizuho Securities USA first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 3 quarters.
Mizuho Securities USA's Biotech Acquisition Company Class A Ordinary Shares position peaked at $4.38M in Q3 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Mizuho Securities USA's 13F filing for Q1 2023, filed 3 May 2023.